SCHEMBL7136752

SCHEMBL7136752

CN(CC(=O)NCc1ccc(CO)cc1)C(=O)OCc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 1/20 0.71
TPSAB1 Q15661 1/20 0.71
ITGB3 P05106 2/20 0.46
ITGAV P06756 2/20 0.46
MAPT P10636 1/20 0.44
NPC1 O15118 2/20 0.44
GAA P10253 3/20 0.44
ALDH1A1 P00352 2/20 0.44
GLA P06280 1/20 0.44
CCR6 P51684 1/20 0.43
PAX8 Q06710 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 2/20 0.43
PLAU P00749 1/20 0.43
MEN1 O00255 1/20 0.43
RAB9A P51151 1/20 0.42
RECQL P46063 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7146925 0.90 PRSS1 (0.71) PRSS1TPSAB1ITGB3ITGAVNPC1
SCHEMBL25380156 0.83 PRSS1 (0.57) PRSS1TPSAB1MAPTALDH1A1CCR6
SCHEMBL11517533 0.83 PRSS1 (0.60) PRSS1TPSAB1ITGB3ITGAVMAPT
SCHEMBL7505433 0.82 PRSS1 (0.59) PRSS1TPSAB1ITGB3ITGAVMAPT
SCHEMBL8426730 0.80 PRSS1 (0.56) PRSS1TPSAB1MAPTNPC1ALDH1A1
SCHEMBL8571304 0.80 PRSS1 (0.63) PRSS1TPSAB1MAPTALDH1A1CCR6
SCHEMBL7135705 0.79 PRSS1 (0.56) PRSS1TPSAB1ITGB3ITGAVMAPT
SCHEMBL7136756 0.79 ALDH1A1 (0.46) PRSS1TPSAB1MAPTALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL9116244 0.79 PRSS1 (0.62) PRSS1TPSAB1MAPTALDH1A1CCR6
SCHEMBL30576761 0.78 CTSL (0.58) PRSS1TPSAB1ITGB3ITGAVALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP PRSS1 17/4885TPSAB1 196/4885ITGB3 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.